Corneal grafting and aggressive medication for corneal defects in graft-versus-host disease following bone marrow transplantation

Eye

Volumn 21, Issue 12, 2007, Pages 1493-1500

  Tarnawska, D ^a   Wylegala E ^a  

^a District Railway Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIGLAUCOMA AGENT; ARTIFICIAL TEAR; CYCLOSPORIN; FLUOROCHINOLONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; PREDNISONE; TACROLIMUS; TOPICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CATARACT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTACT LENS; CORNEA DISEASE; CORNEA DYSTROPHY; CORNEA EPITHELIUM; CORNEA OPACITY; CORNEA PERFORATION; CORNEA STROMA; CORNEA TRANSPLANTATION; CORNEA ULCER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE SYNECHIA; FEMALE; FOLLOW UP; GLAUCOMA; GRAFT SURVIVAL; HUMAN; INTRAOCULAR HYPERTENSION; KERATOPLASTY; LOW DRUG DOSE; MALE; PENETRATING KERATOPLASTY; POSTOPERATIVE INFECTION; REOPERATION; SCAR FORMATION; VISUAL ACUITY;

EID: 37749050861     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702589     Document Type: Article

References (27)

1. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74(4): 1428-1435.
2. Kiang E, Tesavibul N, Yee R, Kellaway J, Przepiorka D. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant 1998; 22(2): 147-151.
3. Claes K, Kestelyn P. Ocular manifestations of graft versus host disease following bone marrow transplantation. Bull Soc Belge Ophtalmol 2000; 277: 21-26.
4. Mencucci R, Rossi Ferrini C, Bosi A, Volpe R, Guidi S, Salvi G. Ophthalmological aspects in allogeneic bone marrow transplantation: Sjogren-like syndrome in graft-versus-host disease. Eur J Ophthalmol 1997; 7(1): 13-18.
5. Calissendorff B, el Azazi, M. Lonnqvist B. Dry eye syndrome in long-term follow-up of bone marrow transplanted patients. Bone Marrow Transplant 1989; 4(6): 675-678.
6. Bray LC, Carey PJ, Proctor SJ, Evans RG, Hamilton PJ. Ocular complications of bone marrow transplantation. Br J Ophthalmol 1991; 75(10): 611-614.
7. Arocker-Mettinger E, Skorpik F, Grabner G, Hinterberger W, Gadner H. Manifestations of graft-versus-host disease following allogeneic bone marrow transplantation. Eur J Ophthalmol 1991; 1(1): 28-32.
8. Tsubota K, Kaido M, Moden YU, Satake Y, Bissen-Mijajima H, Schimazaki JH. A new surgical technique for deep lamellar keratoplasty with single running suture adjustment. Am J Ophthalmol 1998; 126(1): 1-8.
9. Wylegala E, Tarnawska D, Dobrowolski D. Deep lamellar keratoplasty for various corneal lesions. Eur J Ophthalmol 2004; 14: 467-472.
10. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31(7): 579-583.
11. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000; 25(10): 1101-1103.
12. Faulkner WJ, Varley GA. Corneal diagnostic techniques. In: Krachmer JH, Mannis MJ, Holland EJ (eds). Cornea. Fundamentals of Cornea and External Disease, Vol. 1. Mosby:PHiladelphia, 1996 pp 275-281.
13. Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology 2001; 108(9): 1682-1687.
14. Solomon A, Ellies P, Anderson DF, Touhami A, Grueterich M, Espana EM et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology 2002; 109(6): 1159-1166.
15. Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83(10): 1125-1130.
16. West RH, Szer J, Pedersen JS. Ocular surface and lacrimal disturbances in chronic graft-versus-host disease: The role of conjunctival biopsy. Aust N Z J Ophthalmol 1991; 19(3): 187-191.
17. Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishida S et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001; 42(1): 111-119.
18. Kaido M, Goto E, Dogru M, Tsubota K. Punctal occlusion in the management of chronic Stevens-Johnson syndrome. Ophthalmology 2004; 111 5): 895-900.
19. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999; 106(10): 1984-1989.
20. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998; 17(4): 565-596.
21. Vajpayee RB, Mukerji N, Tandon R, Sharma N, Pandey RM, Biswas NR et al. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br J Ophthalmol 2003; 87(11): 1312-1316.
22. Lavid FJ, Herreras JM, Calonge M, Saornil MA, Aguirre C. Calcareous corneal degeneration: Report of two cases. Cornea 1995; 14 1): 97-102.
23. Schlotzer-Schrehardt U, Zagorski Z, Holbach LM, Hofmann-Rummelt C, Naumann GO. Corneal stromal calcification after topical steroid-phosphate therapy. Arch Ophthalmol 1999; 117(10): 1414-1418.
24. Dursun D, Monroy D, Knighton R, Tervo T, Vesaluoma M, Carraway K et al. The effects of experimental tear film removal on corneal surface regularity and barrier function. Ophthalmology 2000; 107(9 : 1754-1760.
25. Claerhout I, Beele H, Van den Abeele K, Kestelyn P. Therapeutic penetrating keratoplasty: Clinical outcome and evolution of endothelial cell density. Cornea 2002; 21(7): 637-642.
26. Pleyer U, Bertelmann E, Rieck P, Hartmann C. Outcome of penetrating keratoplasty in rheumatoid arthritis. Ophthalmologica 2002; 216 4): 249-255.
27. Jabs DA, Wingard J, Green WR, Farmer ER, Vogelsang G, Saral R. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 1989; 107(9): 1343-1348.